Drug Trial Radar · NCT07109700
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Apr 30, 2025
Primary completion
Jan 31, 2026
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety, immunogenicity, and pharmacokinetic (PK) characteristics of HDM1005 in subjects with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control after diet/exercise or metformin therapy. A total of 216 subjects will be enrolled. All subjects will be stratified by baseline HbA1c levels (≤8.5% or \>8.5%) and prior metformin use, then randomized 1:1:1:1:1:1 to: Group 1 (HDM1005 0.5 mg), Group 2 (HDM1005 1.0 mg), Group 3 (HDM1005 2.0 mg), Group 4 (HDM1005 3.0 mg), Group 5 (Placebo), and Group 6 (open-lable dulaglutide 1.5 mg, active comparator), with 36 subjects in each treatment group. Within each dose cohort (0.5/1.0/2.0/3.0mg), there will be \~45 total subjects (36 HDM1005 + 9 placebo). The 1.0mg, 2.0mg, and 3.0mg cohorts will implement dose titration. The study consists of: 2-week screening, 20-week treatment, and 4-week safety follow-up. The end-of-study visit will be conducted 28 days after the last administration cycle.
Conditions
- Type 2 Diabetes
Interventions
HDM1005 1Drug
administered SC, QW, 20 weeks
HDM1005 2Drug
administered SC, QW, 20 weeks
HDM1005 3Drug
administered SC, QW, 20 weeks
HDM1005 4Drug
administered SC, QW, 20 weeks
PlaceboDrug
administered SC, QW, 20 weeks
Dulaglutide 1.5 MGDrug
administered SC, QW, 20 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline, Week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.